207 related articles for article (PubMed ID: 21141726)
1. Histone modifications in cancer biology and prognosis.
Kurdistani SK
Prog Drug Res; 2011; 67():91-106. PubMed ID: 21141726
[TBL] [Abstract][Full Text] [Related]
2. Global levels of histone modifications predict prognosis in different cancers.
Seligson DB; Horvath S; McBrian MA; Mah V; Yu H; Tze S; Wang Q; Chia D; Goodglick L; Kurdistani SK
Am J Pathol; 2009 May; 174(5):1619-28. PubMed ID: 19349354
[TBL] [Abstract][Full Text] [Related]
3. Global histone modification patterns predict risk of prostate cancer recurrence.
Seligson DB; Horvath S; Shi T; Yu H; Tze S; Grunstein M; Kurdistani SK
Nature; 2005 Jun; 435(7046):1262-6. PubMed ID: 15988529
[TBL] [Abstract][Full Text] [Related]
4. Global levels of specific histone modifications and an epigenetic gene signature predict prostate cancer progression and development.
Bianco-Miotto T; Chiam K; Buchanan G; Jindal S; Day TK; Thomas M; Pickering MA; O'Loughlin MA; Ryan NK; Raymond WA; Horvath LG; Kench JG; Stricker PD; Marshall VR; Sutherland RL; Henshall SM; Gerald WL; Scher HI; Risbridger GP; Clements JA; Butler LM; Tilley WD; Horsfall DJ; Ricciardelli C;
Cancer Epidemiol Biomarkers Prev; 2010 Oct; 19(10):2611-22. PubMed ID: 20841388
[TBL] [Abstract][Full Text] [Related]
5. Interplay between different epigenetic modifications and mechanisms.
Murr R
Adv Genet; 2010; 70():101-41. PubMed ID: 20920747
[TBL] [Abstract][Full Text] [Related]
6. Effect of non-enzymatic glycosylation in the epigenetics of cancer.
Rehman S; Aatif M; Rafi Z; Khan MY; Shahab U; Ahmad S; Farhan M
Semin Cancer Biol; 2022 Aug; 83():543-555. PubMed ID: 33276090
[TBL] [Abstract][Full Text] [Related]
7. Epigenetics in prostate cancer: biologic and clinical relevance.
Jerónimo C; Bastian PJ; Bjartell A; Carbone GM; Catto JW; Clark SJ; Henrique R; Nelson WG; Shariat SF
Eur Urol; 2011 Oct; 60(4):753-66. PubMed ID: 21719191
[TBL] [Abstract][Full Text] [Related]
8. Histone modifications and cancer.
Sawan C; Herceg Z
Adv Genet; 2010; 70():57-85. PubMed ID: 20920745
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic biomarkers in prostate cancer: Current and future uses.
Chiam K; Ricciardelli C; Bianco-Miotto T
Cancer Lett; 2014 Jan; 342(2):248-56. PubMed ID: 22391123
[TBL] [Abstract][Full Text] [Related]
10. Histone modifications as markers of cancer prognosis: a cellular view.
Kurdistani SK
Br J Cancer; 2007 Jul; 97(1):1-5. PubMed ID: 17592497
[TBL] [Abstract][Full Text] [Related]
11. Global levels of histone modifications predict prostate cancer recurrence.
Ellinger J; Kahl P; von der Gathen J; Rogenhofer S; Heukamp LC; Gütgemann I; Walter B; Hofstädter F; Büttner R; Müller SC; Bastian PJ; von Ruecker A
Prostate; 2010 Jan; 70(1):61-9. PubMed ID: 19739128
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic therapy of cancer with histone deacetylase inhibitors.
Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
[TBL] [Abstract][Full Text] [Related]
13. The expanding role of epigenetics in the development, diagnosis and treatment of prostate cancer and benign prostatic hyperplasia.
Dobosy JR; Roberts JL; Fu VX; Jarrard DF
J Urol; 2007 Mar; 177(3):822-31. PubMed ID: 17296351
[TBL] [Abstract][Full Text] [Related]
14. Targeting epigenetics for cancer therapy.
Park JW; Han JW
Arch Pharm Res; 2019 Feb; 42(2):159-170. PubMed ID: 30806885
[TBL] [Abstract][Full Text] [Related]
15. New anti-cancer strategies: epigenetic therapies and biomarkers.
Balch C; Montgomery JS; Paik HI; Kim S; Kim S; Huang TH; Nephew KP
Front Biosci; 2005 May; 10():1897-931. PubMed ID: 15769674
[TBL] [Abstract][Full Text] [Related]
16. Dysregulation of Sirtuin 2 (SIRT2) and histone H3K18 acetylation pathways associates with adverse prostate cancer outcomes.
Damodaran S; Damaschke N; Gawdzik J; Yang B; Shi C; Allen GO; Huang W; Denu J; Jarrard D
BMC Cancer; 2017 Dec; 17(1):874. PubMed ID: 29262808
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
[TBL] [Abstract][Full Text] [Related]
18. Histone onco-modifications.
Füllgrabe J; Kavanagh E; Joseph B
Oncogene; 2011 Aug; 30(31):3391-403. PubMed ID: 21516126
[TBL] [Abstract][Full Text] [Related]
19. Identification of Epigenetic Biomarkers of Lung Adenocarcinoma through Multi-Omics Data Analysis.
Kikutake C; Yahara K
PLoS One; 2016; 11(4):e0152918. PubMed ID: 27042856
[TBL] [Abstract][Full Text] [Related]
20. p38-MAPK/MSK1-mediated overexpression of histone H3 serine 10 phosphorylation defines distance-dependent prognostic value of negative resection margin in gastric cancer.
Khan SA; Amnekar R; Khade B; Barreto SG; Ramadwar M; Shrikhande SV; Gupta S
Clin Epigenetics; 2016; 8(1):88. PubMed ID: 27588146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
